MedTrace Logo

Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients

NCT00735761 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 201

Last updated 2008-08-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the episode duration of a herpes labialis recurrence in immunocompromised patients treated with ME-609 or Acyclovir.

Conditions

  • Herpes Labialis

Interventions

DRUG

ME-609

Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application

DRUG

Acyclovir in ME-609 vehicle (5% acyclovir)

Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application

Sponsors & Collaborators

  • Medivir

    lead INDUSTRY

Principal Investigators

  • Anders Sönnerborg, MD PhD Prof. · Clinical Virology, F68, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2007-09-30
Completion
2007-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00735761 on ClinicalTrials.gov